By: Benedette Cuffari, BS Toxicology Candidate c/o 2015 – Hemophilia B is an inherited bleeding disorder that is caused by a substantially reduced or complete lack of blood clotting factor IX. Therefore, people suffering from hemophilia B experience bleeding episodes that cause pain, irreversible joint damage, and life threatening hemorrhages. Approximately 28,000 people are currently…

By: Kevin Lin, PharmD Candidate c/o 2015 — The FDA recently completed an observational cohort study that compared Pradaxa® (dabigatran) to warfarin for rates of ischemic stroke, intracranial hemorrhage, major gastrointestinal bleed, myocardial infarction, and death. The study enrolled more than 134,000 patients, with 64% over the age of 65 and found a lower risk…

By: Diana Gritsenko, PharmD Candidate 2015 – Multiple complications can arise during pregnancy. While venous thromboembolism (VTE) has a prevalence rate of just 0.06% it is one of the leading causes of maternal mortality. It is recommended that at-risk pregnant women receive anticoagulation therapy for a minimum of 3 months and VTE prophylaxis for the…

By: Tamara Yunusova, Senior Staff Editor – After a lengthy fifteen-year hiatus in recombinant drug approvals, FDA-approved Recombinant Coagulation Factor IX (Rixubis) has mounted to the forefront of Hemophilia B drug therapy. The recombinant coagulation factor gained orphan drug approval on June 26, 2013 for routine prophylaxis, control of bleeding episodes, and perioperative management in…

Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are…

By Omar Khalid Pharm.D. Candidate c/o 2014 – The outpour of a multitude of new oral anticoagulants in recent years has health care professionals questioning whether they should switch the patients over, and what new agents should be used. With the recent addition of dabigatran (Pradaxa®) in October 2010, rivaroxaban (Xarelto®) in November 2011, and…

By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1  This occurred one month after its approval in  Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is…

By Lunbao (Jerry) Huang, Pharm.D. Candidate c/o 2013 – Over the last two decades, there has been an increasing focus on hepatocellular carcinoma (HCC, most commonly known as liver cancer).  In the United States, as of 2011, there have been an estimated 26,190 new cases and 19,590 deaths from both hepatic and intrahepatic bile duct cancer.  Defined by the…